(PharmaNewsWire.Com, April 19, 2022 ) The Cardiac Marker Analyzer Market is bound to witness stupendous growth going forward. With advancements in technology, healthcare organizations are into the development of a holistic strategy for building awareness regarding advanced healthcare infrastructure. eBooks and blog posts are also being used to increase the benevolence amongst patients. The healthcare vertical is expected to move in this direction shortly.
Global demand for cardiac marker analyzers is projected to witness over 4.5% year on year growth in 2019. As indicated by PMR in a newly published research intelligence study, North America remains the top consumer market for cardiac marker analyzers manufacturers, and the region’s market value is projected to cross US$ 285 million in 2019.
Nearly 17% of the global population will be above 65 years of age by the end of 2050, as projected by NIH (National Institutes of Health). Whereas, WHO (World Health Organization) indicates that around 13% of the worldwide population is currently suffering from obesity. While both the aforementioned factors intersect at a higher risk of acquiring cardiovascular diseases, it is more likely that the adoption of cardiac market analyzers will be on the rise in coming years.
The growing need for early detection of rapidly prevailing CVDs such as myocardial infarction and angina pectoris is likely to push prospects for cardiac marker analyzers in the near future. A rising trend of individualized treatment and real-time results targeting early patient diagnostics is playing a crucial role popularizing the demand for cardiac marker analyzers.
With ascending significance of disease management, the devices that help manage the disease progression rate are gathering significant momentum in recent years – subsequently encouraging sales of cardiac marker analyzers.
Laboratory diagnostics are identified to hold promising opportunities for manufacturers based on developing economies such as India, China, Brazil, and Japan. These emerging markets are projected to remain highly attractive owing to the briskly progressing R&D platform.
Drug Development Related Opportunities
Growing use of cardiac marker analyzers in drug development as well as lab diagnostics continues to stimulate innovation and adoption, indicates the report.
“Visibly growing preference for Troponin over other conventional markers in diagnosis of heart attack is the key trend shaping the revenue growth of cardiac marker analyzers landscape,” explains the analyst at the company. Adding further, “The remarkable inadequacy in existing drug development processes for CVDs is another strong factor broadening the scope for penetration of cardiac marker analyzers at a global level,” says the analyst.
While around 80% share of the global revenue through sales of cardiac marker analyzers belongs to the top industry players, the rest is covered by a number of smaller companies that currently operate at a local or regional level. Abbott Laboratories, Beckman Coulter, Inc., F. Hoffmann-La Roche Ltd., Siemens AG, and a few others are thoroughly profiled in the PMR report.
Abbott acquired St. Jude Medical the last year, with an objective to reap benefits of the latter’s strong global position in thriving cardiac areas such as heart failure, atrial fibrillation, structural heart, and chronic pain complement.
Earlier this year, Beckman Coulter Inc. (Danaher Corporation) received the clearance approval by Health Canada for the new high-sensitivity troponin (hsTnI) assay. More recently, Siemens AG launched the Troponin test kit that has been a key marker used diagnosing heart attack.
Besides M&A, strategic collaborations with local distributors, suppliers, wholesalers, and retailers is also likely to remain one of the key strategies of competitors in cardiac marker analyzers landscape. Several leading companies are also signing contractual agreements with channel partners such as associations and universities over the manufacturing of cardiac market test kits.
At an estimated 5% yearly growth in 2019, North America remains the top performing market for cardiac marker analyzers. While chemiluminiscence immunoassay (CLIA) analyzers account for more than 30% share of the region’s total revenue, whereas diagnostic centers continue to make up for over half of the market value of the region. Enzymeimmunoassay (EIA) analyzers are however projected for highly attractive investment opportunities in coming years.
Europe’s market, the second largest consumer of cardiac marker analyzers, is predominantly driven by chemiluminiscence immunoassay (CLIA) analyzers, followed by MICA analyzers i.e. presumably the most lucrative segment for key players.
Cardiovascular Information Systems Market - Global market for cardiovascular information systems represents an absolute $ opportunity of more than US$ 45 Mn in 2017 & an opportunity of more than US$ 600 Mn between 2016-2024.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: